Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Ivermectin for COVID-19
NCT04681053Phase 3Unknown
- Sponsor
- Mansoura University
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ivermectin in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Mansoura University. Primary endpoint: Rate of virological cure by RT-PCR for COVID-19 at 1 year. Status: unknown.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04681053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681053.